ASH 2022 | EMN 27: Phase II study of belantamab mafodotin in patients with R/R AL amyloidosis
Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, outlines results from EMN 27 (NCT04617925), an ongoing Phase II trial evaluating the efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory (R/R) AL amyloidosis. So far, findings suggest high efficacy of this agent in patients with R/R AL amyloidosis, including encouraging partial and complete responses. Nevertheless, this treatment was also associated with a high incidence of keratopathy. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
GSK: Honoraria; Takeda: Honoraria; Pfizer: Honoraria, Research Funding; Genesis Pharma: Honoraria; Janssen: Honoraria, Research Funding; Amgen: Honoraria, Research Funding.
